Skip to content
HowShorted

Paratek Pharmaceuticals, Inc. short interest in 2020

In 2020, Paratek Pharmaceuticals, Inc.'s disclosed short interest ran from 23.33% of shares outstanding on 15 Jan 2020 to 9.52% on 31 Dec 2020, a change of -13.81 percentage points. The year's high was 23.33% on 15 Jan 2020 and its low 7.81% on 14 Aug 2020, averaging 11.87% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.34 days on 14 Feb 2020. Full history: Paratek Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023

Aggregate net short position time series for Paratek Pharmaceuticals, Inc. in 2020

2020 in figures

Start of year
23.33% (15 Jan 2020)
End of year
9.52% (31 Dec 2020)
Change
-13.81 pp
High
23.33% (15 Jan 2020)
Low
7.81% (14 Aug 2020)
Average
11.87%
Highest days to cover
15.34 (14 Feb 2020)
SEC filings marked
4

Every report in 2020

Paratek Pharmaceuticals, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202023.33%6.98
31 Jan 202022.42%11.23
14 Feb 202022.70%15.34
28 Feb 202021.12%5.42
13 Mar 202018.41%6.2510-K filed
31 Mar 202016.74%7.19
15 Apr 202015.96%8.90
30 Apr 20209.89%8.18
15 May 20208.37%6.5410-Q filed
29 May 20208.40%9.74
15 Jun 20208.41%6.81
30 Jun 20209.14%7.12
15 Jul 20208.54%7.45
31 Jul 20208.14%5.40
14 Aug 20207.81%10.3710-Q filed
31 Aug 20208.21%13.48
15 Sep 20208.63%3.55
30 Sep 20208.33%5.06
15 Oct 20207.99%12.30
30 Oct 20208.38%13.35
13 Nov 20208.42%9.7410-Q filed
30 Nov 20207.89%12.75
15 Dec 20208.18%10.70
31 Dec 20209.52%11.01

See also: Paratek Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.